))
Move over CAR-T: The potential of NK cells in cell therapy
Manage episode 421161003 series 3079777
Content provided by pharmaphorum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by pharmaphorum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
On today’s podcast, Dr. Fred Aslan, CEO of Artiva Biosciences, joins host Jonah Comstock to talk more about this newer avenue in cell therapy. They discuss the potential of NK cells to provide effective allogeneic cell therapy, the potential of the therapy in auto-immune disease, and the importance of a robust manufacturing process that can get a high number of doses from a small amount of donated tissue.
214 episodes
Share
